Molecular biology of PCSK9: its role in LDL metabolism
JD Horton, JC Cohen, HH Hobbs - Trends in biochemical sciences, 2007 - cell.com
JD Horton, JC Cohen, HH Hobbs
Trends in biochemical sciences, 2007•cell.comProprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine
protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls
the level of LDL in plasma. Mutations that increase PCSK9 activity cause
hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9
have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism
of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower …
protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls
the level of LDL in plasma. Mutations that increase PCSK9 activity cause
hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9
have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism
of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower …
Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.
cell.com